To explore whether the regulatory process in question is fit for purpose, the Food & Drug Law Institute’s Food and Drug Policy Forum has published papers by those for and against GE animals, using AquaBounty Technologies’ experiences as a case study.
(AquaBounty is seeking to gain approval for its genetically engineered AquAdvantage Atlantic salmon, which includes a gene from the faster-growing Pacific Chinook salmon enabling it to reach maturity twice as quickly as standard Atlantic salmon.)
In the red corner is Tim Schwab, senior researcher at anti-GM lobby group Food & Water Watch, who has penned the article: ‘Is FDA Ready to Regulate the World’s First Biotech Food Animal?’ (spoiler alert – he thinks ‘NO’). In the blue corner are Dr Alison L. Van Eenennaam, Dr William M. Muir, and Dr Eric M. Hallerman*, who have penned the response: ‘Is Unaccountable Regulatory Delay and Political Interference Undermining the FDA and Hurting American Competitiveness?’ (spoiler alert – they think ‘YES’)
Read the full story here: GE salmon… Is the FDA’s review process for genetically engineered animals fit for purpose?
